Jose Moreno Toscano Net Worth

Jose Moreno Toscano biography

Jose Antonio Moreno Toscano serves as Independent Director of the Company. ince April 2018, Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc., the US subsidiary of LFB Group, a global integrated biopharmaceutical company dedicated to developing innovative products through recombinant, plasma derived and cell therapy technology. From July 2017 to March 2018, Mr. Moreno Toscano served as President of Safe Harbor Compliance and Clinical Services, an integrated health care services provider dedicated to providing specialty pharmaceuticals and ancillary services in primary care offices. From July 2016 to September 2018, he also served as a member of the board of directors. From March 2016 to March 2017, Mr. Moreno Toscano served as CEO, Americas, for Kompan Inc., a US subsidiary of Kompan A/S, a world leader in playground equipment. From March 2006 to March 2016, Mr. Moreno Toscano served as President of ALK-Abello Inc., a US subsidiary of ALK-Abello A/S, a pharmaceutical company that is a world leader in allergy immunotherapy. Prior to ALK-Abello, he was the Chief Financial Officer of Applus A/S, a market leader in automotive inspection services, and prior to Applus, he held several positions at Christian Hansen Holding A/S, a global leader in pharmaceutical manufacturing and producer of natural ingredients for the food, beverage, dietary supplement and agricultural industries. Mr. Moreno Toscano holds a Master’s Degree in Law from the Universidad de Murcia in Spain and an MBA in International Finance and Strategy from the Ecole Nationale des Ponts et Chaussees in Paris.

How old is Jose Toscano?

Jose Toscano is 47, he's been the Independent Director of Genprex Inc since 2020. There are 10 older and 2 younger executives at Genprex Inc. The oldest executive at Genprex Inc is William Wilson, 70, who is the Independent Director.

What's Jose Toscano's mailing address?

Toscano's mailing address filed with the SEC is 3300 BEE CAVE ROAD, #650-227, AUSTIN, TX, 78746.

Insiders trading at Genprex Inc

Over the last 7 years, insiders at Genprex Inc have traded over $0 worth of Genprex Inc stock and bought 156,300 units worth $607,092 . The most active insiders traders include Ryan M. Confer, Christy M. Nance, and Jack A Roth. On average, Genprex Inc executives and independent directors trade stock every 205 days with the average trade being worth of $14,575. The most recent stock trade was executed by John Rodney Varner on 21 April 2023, trading 19,000 units of GNPX stock currently worth $20,140.

What does Genprex Inc do?

genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur

Genprex Inc executives and stock owners

Genprex Inc executives and other stock owners filed with the SEC include:

• Ryan Confer,
  Chief Financial Officer
• John Rodney Varner,
  Co, Founder, Pres, CEO, Sec. & Chairman
• J. Rodney Varner,
  Chairman of the Board, President, Chief Executive Officer, Secretary
• Catherine M. Vaczy,
  Exec. VP, Gen. Counsel & Chief Strategy Officer
• Catherine M. Vaczy Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer
• Ryan M. Confer M.S.,
  Chief Financial Officer
• William Wilson,
  Independent Director
• Jose Moreno Toscano,
  Independent Director
• Brent Longnecker,
  Independent Director
• Catherine Vaczy,
  Executive Vice President, Chief Strategy Officer
• Michael Redman,
  Chief Operating Officer, Executive Vice President
• David M. Schloss,
  Sr. VP of HR
• Greg Jancarik C.M.A., CPA, M.B.A.,
  Corp. Controller
• Dr. Mark S. Berger M.D.,
  Chief Medical Officer
• Dr. Hemant Kumar C.P.M., EMBA, Ph.D.,
  Chief Manufacturing & Technology Officer
• Dr. Jack A. Roth F.A.C.S., FACS, M.D.,
  Chairman of Scientific & Medical Advisory Board
• Dr. William E. Gannon Jr.,
  Member of Clinical Advisory Board & VP of Regulatory Affairs
• Thomas C. Gallagher Esq.,
  Sr. VP of Intellectual Property & Licensing
• Kalyn Dabbs,
  Sr. Mang. of Communications & Marketing
• Christy M. Nance,
  10% owner
• Jack A Roth,
  10% owner
• Viet An Hoan Ly,
  10% owner
• Inc. Genprex,,
  Chief Executive Officer
• Robert W. Pearson,
  Director
• David E. Friedman,
  Director
• Julien L Pham,
  President & COO
• Mark Stanley Berger,
  Chief Medical Officer
• Hermant Kumar,
  Chief Mfgr & Tech Officer